Site Editor
William J. Gradishar, MD, FACP, FASCO
William J. Gradishar, MD, FACP, FASCO
Posted: Tuesday, September 24, 2024
The phase II Neo-CheckRay trial, conducted by Alex De Caluwé, MD, of the Institut Jules Bordet, Brussels, and colleagues, is reportedly the first prospective study of its kind to evaluate the addition of stereotactic body radiation therapy (SBRT) to PD-L1 inhibitors and chemotherapy for high-risk, early-stage, hormone receptor (HR)-positive, HER2-negative breast cancer. Presented during the European Society for Medical Oncology (ESMO) Congress 2024 (Abstract LBA10), the results of this study suggest this treatment combination may prove to be a viable option for this patient population.
“The addition of durvalumab [and/or] oleclumab numerically increases pathologic complete response and residual cancer burden rates compared to neoadjuvant chemotherapy plus SBRT,” the investigators concluded. “Ongoing translational research will shed light on the mechanisms of response.”
A total of 147 patients with newly diagnosed, high-risk, invasive, HR-positive, HER2-negative breast cancer were enrolled. Participants were randomly assigned 1:1:1 to receive neoadjuvant paclitaxel plus SBRT followed by dose-dense epirubicin/cyclophosphamide (arm 1) with or without durvalumab (arm 2) and/or oleclumab (arm 3; n = 45 each). Adjuvant endocrine therapy and standard radiation therapy were initiated after surgery.
Of the randomly assigned patients, 135 were evaluable for the intent-to-treat analysis; 9 were characterized as having MammaPrint low-risk disease. A total of 133 patients underwent surgery, with the most common being breast-conserving surgery, followed by mastectomy.
Grade 3 or 4 treatment-related adverse events were mostly reported among patients in arm 3 (70.8%), followed by arms 2 (64.7%) and 1 (27.1%). Of note, this trend was similar regarding treatment discontinuation because of adverse events. Furthermore, no adverse events were attributed to SBRT, and no deaths occurred on treatment.
Disclosure: For full disclosures of the study authors, visit cslide.ctimeetingtech.com.
JNCCN Spotlights
